Evidence map›Paper›PMID 41019048›Full record

ArticleFrontiers in immunology2025

Seroprevalence of antibodies to

Charles Mulamba, Wilmina F Kalinga, Ivanny Mtaka, Linda O Lazaro, Janeth Kamage, Irene Nkumama, Olukayode G Odufuwa, Katharina Kreppel, David Mekhaiel, Kazutoyo Miura and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Charles MulambaInterventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania.
Wilmina F KalingaInterventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania.
Ivanny MtakaInterventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania.
Linda O LazaroNelson Mandela African Institution of Science and Technology, Arusha, Tanzania.
Janeth KamageInterventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania.
Irene NkumamaEuropean Vaccine Initiative, Heidelberg, Germany.
Olukayode G OdufuwaInterventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania.
Katharina KreppelNelson Mandela African Institution of Science and Technology, Arusha, Tanzania.
David MekhaielTransmission-blocking Malaria Vaccine Group, Jenner Institute, University of Oxford, Oxford, United Kingdom.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
Carole A LongLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
Ally I OlotuInterventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania.
Chris WilliamsTransmission-blocking Malaria Vaccine Group, Jenner Institute, University of Oxford, Oxford, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transmission-blocking vaccines are among the novel tools under development for malaria control and elimination. Understanding the human immune response to the sexual stages of

Indexed as

Antibodies, ProtozoanAntigens, ProtozoanMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsAdolescentAdultChildChild, PreschoolFemaleHumansImmunoglobulin GMaleMembrane GlycoproteinsMiddle AgedSeroepidemiologic StudiesAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GMembrane GlycoproteinsPfs230 antigen, Plasmodium falciparumpfs48-45 protein, Plasmodium falciparumProtozoan Proteinsand Pfs48/45gametocytesmalaria transmissionPfs230D1MPfs25Plasmodium falciparumTanzaniatransmission-blocking vaccines

Identifiers

PMID41019048
PMCPMC12460233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.